These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 20202594

  • 41. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy.
    Hickman RA, Denniston AK, Yee CS, Toescu V, Murray PI, Gordon C.
    Lupus; 2010 Mar; 19(3):327-9. PubMed ID: 19900982
    [Abstract] [Full Text] [Related]

  • 42. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
    Terrier B, Mouthon L.
    Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
    [Abstract] [Full Text] [Related]

  • 43. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 44. Aberrant B cell selection and activation in systemic lupus erythematosus.
    Kil LP, Hendriks RW.
    Int Rev Immunol; 2013 Aug; 32(4):445-70. PubMed ID: 23768157
    [Abstract] [Full Text] [Related]

  • 45. B-cell targeted treatments for lupus: the journey counts as much as the destination.
    Falgarone G, Dhote R, Boissier MC.
    Joint Bone Spine; 2012 Oct; 79(5):437-40. PubMed ID: 22480746
    [Abstract] [Full Text] [Related]

  • 46. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
    Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D, Eisenberg RA, Luning Prak ET.
    Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
    [Abstract] [Full Text] [Related]

  • 47. [Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case].
    Sabugo F, Llanos C, Soto L, Gutiérrez J, Cuchacovich M.
    Rev Med Chil; 2005 Jun; 133(6):681-4. PubMed ID: 16075133
    [Abstract] [Full Text] [Related]

  • 48. Effect of rituximab in refractory SLE: inhibition of Th1?
    Okamoto H.
    Rheumatology (Oxford); 2006 Jan; 45(1):121-2; author reply 122-3. PubMed ID: 16361704
    [No Abstract] [Full Text] [Related]

  • 49. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.
    Lin W, Seshasayee D, Lee WP, Caplazi P, McVay S, Suto E, Nguyen A, Lin Z, Sun Y, DeForge L, Balazs M, Martin F, Zarrin AA.
    Arthritis Rheumatol; 2015 Jan; 67(1):215-24. PubMed ID: 25303150
    [Abstract] [Full Text] [Related]

  • 50. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    Yap DYH, Chan TM.
    Int J Mol Sci; 2019 Dec 10; 20(24):. PubMed ID: 31835612
    [Abstract] [Full Text] [Related]

  • 51. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].
    Takasaki Y.
    Nihon Jinzo Gakkai Shi; 2012 Dec 10; 54(5):598-602. PubMed ID: 22991839
    [No Abstract] [Full Text] [Related]

  • 52. B cells targeting therapy in the management of systemic lupus erythematosus.
    Lee WS, Amengual O.
    Immunol Med; 2020 Mar 10; 43(1):16-35. PubMed ID: 32107989
    [Abstract] [Full Text] [Related]

  • 53. From mechanism to therapies in systemic lupus erythematosus.
    Paley MA, Strand V, Kim AH.
    Curr Opin Rheumatol; 2017 Mar 10; 29(2):178-186. PubMed ID: 28118202
    [Abstract] [Full Text] [Related]

  • 54. Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus.
    Mackern-Oberti JP, Llanos C, Riedel CA, Bueno SM, Kalergis AM.
    Immunology; 2015 Dec 10; 146(4):497-507. PubMed ID: 26173489
    [Abstract] [Full Text] [Related]

  • 55. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.
    Nakayamada S, Iwata S, Tanaka Y.
    Int J Rheum Dis; 2015 Feb 10; 18(2):208-18. PubMed ID: 25557245
    [Abstract] [Full Text] [Related]

  • 56. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
    Sanchez-Niño MD, Ortiz A.
    Nephrol Dial Transplant; 2015 Mar 10; 30(3):394-400. PubMed ID: 24914092
    [Abstract] [Full Text] [Related]

  • 57. Recent Advances in Lupus B Cell Biology: PI3K, IFNγ, and Chromatin.
    Bacalao MA, Satterthwaite AB.
    Front Immunol; 2020 Mar 10; 11():615673. PubMed ID: 33519824
    [Abstract] [Full Text] [Related]

  • 58. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I.
    Arthritis Rheum; 2004 Nov 10; 50(11):3580-90. PubMed ID: 15529346
    [Abstract] [Full Text] [Related]

  • 59. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.
    Walsh M, Jayne D.
    Kidney Int; 2007 Sep 10; 72(6):676-82. PubMed ID: 17609693
    [Abstract] [Full Text] [Related]

  • 60. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B.
    Br J Haematol; 2002 Feb 10; 116(2):465-7. PubMed ID: 11841453
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.